The revenues from sales recorded in the first six months of 2016 by Antibiotice SA counted for 143.8 million lei, up by 9pct against the similar period of 2015, while the gross profit in the same interval of time grew by 13pct to 18.85 million lei, according to the financial results communicated by the company on Monday to the Bucharest Stock Exchange (BVB).
At the same time, after January-June 2016, Antibiotice SA reports a net turnover of 89.4 million lei, up by 3.5pct as compared to the similar period of 2015.
The incomes from the sales on external markets reached 54.5 million lei, by 18pct over the level reported in the first semester of 2015, when it resulted in 46.26 million lei.
“In the first half of 2016, the export of finished products grew significantly. The main growth was recorded on the US market, with deliveries doubled against the reference period of 2015. Antibiotice SA is exporting to the USA injectable anti-infective penicillin products. Likewise, a doubling of exports was recorded in the European area, while in other zones, such as Russia and the Independent States’ Community, the Middle East and Southeastern Asia the exports nearly remained at the level of 2015 from reasons related to the geopolitical situation in certain markets, too. The most significant increases recorded for the injectable products (used in hospitals to treating infections), capsules and suppositories,” the release by the BVB informs.
On the other hand, the revenues from the domestic sales grew by 3.5pct in H1.
According to the BVB website, the Antibiotice SA Company, one of the most important companies with full Romanian capital was established in 1955, and in 1997 it was listed at the BVB. Starting with 2000, on the Iasi platform investments worth over 30 million euro were carried.
The company’s basic activity is the manufacturing of oral solid anti-infective medicines as it is the only pharmaceutical company in Romania that splits apart sterile powders for injectable anti-infective treatments.
Antibiotice SA of Iasi is a leader for the Romanian hospitals-dedicated production, has the most significant ratio for the topical products (ointments, creams, gels) for the Romanian market, at the same time developing an important segment of products for the cardiovascular system, the central nervous system and oncology.